Primary amyloidosis differential diagnosis: Difference between revisions
Jump to navigation
Jump to search
Line 5: | Line 5: | ||
==Overview== | ==Overview== | ||
* Differentiating Primary amyloidosis from Other Diseases | |||
{| | {| | ||
! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Organ System Involvement}} | ! style="background: #4479BA; width: 200px;" |{{fontcolor|#FFF|Organ System Involvement}} | ||
! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Differential Diagnosis}} | ! style="background: #4479BA; width: 200px;" |{{fontcolor|#FFF|Differential Diagnosis}} | ||
! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Causes}} | ! style="background: #4479BA; width: 200px;" |{{fontcolor|#FFF|Causes}} | ||
! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Clinical Features}} | ! style="background: #4479BA; width: 200px;" |{{fontcolor|#FFF|Clinical Features}} | ||
! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Laboratory Findings}} | ! style="background: #4479BA; width: 200px;" |{{fontcolor|#FFF|Laboratory Findings}} | ||
! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Gold Standard Test}} | ! style="background: #4479BA; width: 200px;" |{{fontcolor|#FFF|Gold Standard Test}} | ||
! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Therapy}} | ! style="background: #4479BA; width: 200px;" |{{fontcolor|#FFF|Therapy}} | ||
|- | |- | ||
! rowspan="8" style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |Nephrotic Syndrome and Real Failure | ! rowspan="8" style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |Nephrotic Syndrome and Real Failure | ||
Line 41: | Line 42: | ||
* Proteinuria | * Proteinuria | ||
* Urinary hyaline and fatty casts | * Urinary hyaline and fatty casts | ||
*Hypercholesterolemia | |||
* | * | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* Biopsy: | * Biopsy: | ||
** Diffuse glomerular deposition of amorphous hyaline material (nodular pattern), in mesangium (weakly staining with periodic acid-Schiff (PAS) | |||
* Diffuse glomerular deposition of amorphous hyaline material (nodular pattern), in mesangium (weakly staining with periodic acid-Schiff (PAS) | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |Diabetic Nephropathy | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |Diabetic Nephropathy | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* Hyperfiltration | |||
* Constriction of efferent arteriole | |||
* Microalbuminuria | |||
* Mesangial proliferation | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* Nocturia | |||
* Fatigue | |||
* Pruritis | |||
* Peripheral edema | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* Hyperglycemia (random plasma glucose ≥200 mg/dL) | |||
* Proteinuria | |||
* Glucosuria | |||
* HbA1C ≥6.5% (48 mmol/mol). <br /> | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* Biopsy: | |||
** PAS positive Kimmelstiel-Wilson nodules | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |Minimal Change Disease | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |Minimal Change Disease | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* Upper respiratory tract infection | |||
* Allergy to bee sting | |||
* NSAID | |||
* Gold | |||
* Penicillamine | |||
* Ampicillin | |||
* Mercury | |||
* Hodgkin's and non-Hodgkin's lymphoma | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
Line 98: | Line 121: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Organ System Involvement}} | ! style="background: #4479BA; width: 200px;" |{{fontcolor|#FFF|Organ System Involvement}} | ||
! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Differential Diagnosis}} | ! style="background: #4479BA; width: 200px;" |{{fontcolor|#FFF|Differential Diagnosis}} | ||
! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Causes}} | ! style="background: #4479BA; width: 200px;" |{{fontcolor|#FFF|Causes}} | ||
! style="background: #4479BA; width: 300px;" | {{fontcolor|#FFF| Clinical Features}} | ! style="background: #4479BA; width: 300px;" |{{fontcolor|#FFF| Clinical Features}} | ||
! style="background: #4479BA; width: 300px;" | {{fontcolor|#FFF|Laboratory Findings}} | ! style="background: #4479BA; width: 300px;" |{{fontcolor|#FFF|Laboratory Findings}} | ||
! style="background: #4479BA; width: 300px;" | {{fontcolor|#FFF|Gold Standard Test}} | ! style="background: #4479BA; width: 300px;" |{{fontcolor|#FFF|Gold Standard Test}} | ||
! style="background: #4479BA; width: 300px;" | {{fontcolor|#FFF|Therapy}} | ! style="background: #4479BA; width: 300px;" |{{fontcolor|#FFF|Therapy}} | ||
|- | |- | ||
| rowspan="6" style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''''Polyneuropathy''''' | | rowspan="6" style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''''Polyneuropathy''''' | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''POEMS syndrome (Demyelinating)''' | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''POEMS syndrome (Demyelinating)''' | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* [[Monoclonal]] [[plasma cell]] proliferation | *[[Monoclonal]] [[plasma cell]] proliferation | ||
* Cytokine storm (IL-1, IL-6, IL-12, TNF alpha, VEGF) | * Cytokine storm (IL-1, IL-6, IL-12, TNF alpha, VEGF) | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* Symmetrical, ascending chronic progressive [[polyneuropathy]] with both [[Sensory system|sensory]] (pin-prick and vibration) and [[Motor skill|motor]] disability ([[Motor skill|motor]] > [[sensory]]) | * Symmetrical, ascending chronic progressive [[polyneuropathy]] with both [[Sensory system|sensory]] (pin-prick and vibration) and [[Motor skill|motor]] disability ([[Motor skill|motor]] > [[sensory]]) | ||
* Generalized/extermity [[pain]] | * Generalized/extermity [[pain]] | ||
* [[Areflexia]] | *[[Areflexia]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
*Increased number of [[Platelet|thrombocytes]] | *Increased number of [[Platelet|thrombocytes]] | ||
Line 125: | Line 148: | ||
*Elevated levels of antitiroglobulin [[antibody]] and antithyroid peroxydase [[antibody]] | *Elevated levels of antitiroglobulin [[antibody]] and antithyroid peroxydase [[antibody]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* [[POEMS syndrome diagnostic criteria|International Myeloma Working Group (IMWG) clinical and laboratory diagnostic criteria]] | *[[POEMS syndrome diagnostic criteria|International Myeloma Working Group (IMWG) clinical and laboratory diagnostic criteria]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[Metabolic syndrome|Metabolic Syndrome]] (Axonal pathology)''' | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[Metabolic syndrome|Metabolic Syndrome]] (Axonal pathology)''' | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* [[Diabetes mellitus]] | *[[Diabetes mellitus]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* Symmetric sensorimotor distal polyneuropathy | * Symmetric sensorimotor distal polyneuropathy | ||
* Asymmetric proximal neuropathy | * Asymmetric proximal neuropathy | ||
* [[Oculomotor nerve palsy|3rd nerve palsy]] | *[[Oculomotor nerve palsy|3rd nerve palsy]] | ||
* [[Carpal tunnel syndrome|Carpel tunnel syndrome]] | *[[Carpal tunnel syndrome|Carpel tunnel syndrome]] | ||
* [[Autonomic neuropathy]] | *[[Autonomic neuropathy]] | ||
* "Glove and stocking" type pain | * "Glove and stocking" type pain | ||
* [[Muscle wasting]] | *[[Muscle wasting]] | ||
* [[Hammer toe|Hammer toes]] | *[[Hammer toe|Hammer toes]] | ||
* [[Polyuria]] | *[[Polyuria]] | ||
* [[Polydipsia]] | *[[Polydipsia]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* Uncontrolled [[hyperglycemia]] | * Uncontrolled [[hyperglycemia]] | ||
* Slowed [[Nerve conduction study|nerve conduction]] | * Slowed [[Nerve conduction study|nerve conduction]] | ||
* [[Small fiber peripheral neuropathy|Small fiber dysfunction]] | *[[Small fiber peripheral neuropathy|Small fiber dysfunction]] | ||
* [[Monofilament|Monofilament testing]] | *[[Monofilament|Monofilament testing]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* [[Fasting blood sugar|Fasting blood sugar level]] greater than equal to 126 mg/dl on 2 separate occasions | *[[Fasting blood sugar|Fasting blood sugar level]] greater than equal to 126 mg/dl on 2 separate occasions | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* [[Diabetes mellitus medical therapy|Anti-diabetic therapy]] | *[[Diabetes mellitus medical therapy|Anti-diabetic therapy]] | ||
* [[Gabapentin]] | *[[Gabapentin]] | ||
* [[Carbamazepine]] | *[[Carbamazepine]] | ||
* [[Foot care]] | *[[Foot care]] | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[Vitamin deficiencies|Vitamin Deficiencies]] (Axonal Pathology)''' | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[Vitamin deficiencies|Vitamin Deficiencies]] (Axonal Pathology)''' | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* [[Vitamin B12 deficiency]] (Decreased [[S-Adenosyl methionine|S-adenosyl methionine]]) | *[[Vitamin B12 deficiency]] (Decreased [[S-Adenosyl methionine|S-adenosyl methionine]]) | ||
* [[Thiamine deficiency|Vitamin B1 deficiency]] | *[[Thiamine deficiency|Vitamin B1 deficiency]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* Primarily [[sensory]] deficits | * Primarily [[sensory]] deficits | ||
* Vibration and [[proprioception]] affected | * Vibration and [[proprioception]] affected | ||
* [[Gait abnormality|Gait abnormalities]] | *[[Gait abnormality|Gait abnormalities]] | ||
* [[Cognitive impairment]] | *[[Cognitive impairment]] | ||
* [[Irritability]] | *[[Irritability]] | ||
* [[Glossitis]] | *[[Glossitis]] | ||
* | * | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* [[Anemia]] ([[Megaloblastic Anemias|megaloblastic]] in case of [[Vitamin B12 deficiency|B12 deficiency]]) | *[[Anemia]] ([[Megaloblastic Anemias|megaloblastic]] in case of [[Vitamin B12 deficiency|B12 deficiency]]) | ||
* Decreased [[serum]] [[Vitamin B12]] levels (< 200 pg/ml) | * Decreased [[serum]] [[Vitamin B12]] levels (< 200 pg/ml) | ||
* [[Methylmalonic acidemia|Elevated methylmalonic acid]] | *[[Methylmalonic acidemia|Elevated methylmalonic acid]] | ||
* | * | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* [[Serum]] [[Vitamin B12]] levels | *[[Serum]] [[Vitamin B12]] levels | ||
* [[Methylmalonic acid|Methylmalonic acid levels]] | *[[Methylmalonic acid|Methylmalonic acid levels]] | ||
* [[Intrinsic factor|Intrinsic factor antibodies]] | *[[Intrinsic factor|Intrinsic factor antibodies]] | ||
* | * | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* [[Vitamin B12]] supplement ([[parenteral]]) | *[[Vitamin B12]] supplement ([[parenteral]]) | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[Guillain-Barré syndrome|Guillain-Barre Syndrome]] (Demyelinating)''' | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[Guillain-Barré syndrome|Guillain-Barre Syndrome]] (Demyelinating)''' | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* [[Anti-ganglioside antibodies|Anti-ganglioside]] and anti-[[myelin]] antibodies | *[[Anti-ganglioside antibodies|Anti-ganglioside]] and anti-[[myelin]] antibodies | ||
* [[Viral]] infections: | *[[Viral]] infections: | ||
**[[Epstein Barr virus]] | **[[Epstein Barr virus]] | ||
** [[Human Immunodeficiency Virus (HIV)|HIV]] | **[[Human Immunodeficiency Virus (HIV)|HIV]] | ||
** [[Cytomegalovirus]] | **[[Cytomegalovirus]] | ||
** [[Varicella Zoster Virus|Varicella Zoster virus]] | **[[Varicella Zoster Virus|Varicella Zoster virus]] | ||
* [[Bacterial]] infections: | *[[Bacterial]] infections: | ||
**[[Campylobacter]] infection | **[[Campylobacter]] infection | ||
** [[Mycoplasma pneumoniae]] | **[[Mycoplasma pneumoniae]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* Rapid onset and quick progression | * Rapid onset and quick progression | ||
* Progression stops after 2-3 weeks | * Progression stops after 2-3 weeks | ||
* Bilateral ascending [[Paraesthesia|paraesthesias]] and [[paralysis]] (generalized) | * Bilateral ascending [[Paraesthesia|paraesthesias]] and [[paralysis]] (generalized) | ||
* [[Muscle weakness|Weakness]] | *[[Muscle weakness|Weakness]] | ||
* [[Ataxia]] | *[[Ataxia]] | ||
* [[Areflexia]] | *[[Areflexia]] | ||
* No fever | * No fever | ||
* 4 sub-types: | * 4 sub-types: | ||
Line 212: | Line 235: | ||
* Clinical diagnostic criteria (progressive weakness of more than two [[limbs]], [[areflexia]], and progression for no more than four weeks) | * Clinical diagnostic criteria (progressive weakness of more than two [[limbs]], [[areflexia]], and progression for no more than four weeks) | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* [[Intravenous]] [[immunoglobulins]] | *[[Intravenous]] [[immunoglobulins]] | ||
* [[Plasma]] exchange | *[[Plasma]] exchange | ||
* [[Mechanical ventilation|Respiratory support]] | *[[Mechanical ventilation|Respiratory support]] | ||
* [[DVT]]/[[PE]] [[prevention]] | *[[DVT]]/[[PE]] [[prevention]] | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[Chronic inflammatory demyelinating polyneuropathy|Chronic Inflammatory Demyelinating Polyneuropathy]] (CIDP) (Mixed axonal and demyelinatiing)''' | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[Chronic inflammatory demyelinating polyneuropathy|Chronic Inflammatory Demyelinating Polyneuropathy]] (CIDP) (Mixed axonal and demyelinatiing)''' | ||
Line 224: | Line 247: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* Slow onset and gradual progression | * Slow onset and gradual progression | ||
* [[Relapse|Relapsing]] and remitting course | *[[Relapse|Relapsing]] and remitting course | ||
* Symmetrical [[Proximal muscle weakness|proximal]] and [[Distal muscle weakness|distal motor]] and [[Sensory system|sensory weakness]] (legs>arms) | * Symmetrical [[Proximal muscle weakness|proximal]] and [[Distal muscle weakness|distal motor]] and [[Sensory system|sensory weakness]] (legs>arms) | ||
* [[Foot drop]] | *[[Foot drop]] | ||
* [[Numbness]], [[tingling]] and [[pain]] | *[[Numbness]], [[tingling]] and [[pain]] | ||
* [[Areflexia]] | *[[Areflexia]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* Elevated [[CSF]] [[protein]] ([[oligoclonal bands]] with normal [[White blood cells|WBCs]]) | * Elevated [[CSF]] [[protein]] ([[oligoclonal bands]] with normal [[White blood cells|WBCs]]) | ||
Line 234: | Line 257: | ||
* Prolonged distal [[Motor skill|motor]] latencies (period between F wave and initial stimulation) | * Prolonged distal [[Motor skill|motor]] latencies (period between F wave and initial stimulation) | ||
* Delayed F wave latencies (recorded from the [[feet]], hence called "F" waves) | * Delayed F wave latencies (recorded from the [[feet]], hence called "F" waves) | ||
* [[MRI]] contrast enhancement and enlargement of [[Vertebra|T2]] [[spinal segments]] | *[[MRI]] contrast enhancement and enlargement of [[Vertebra|T2]] [[spinal segments]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* EFNS/PNS criteria | * EFNS/PNS criteria | ||
* Koski criteria | * Koski criteria | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* [[Corticosteroids]] | *[[Corticosteroids]] | ||
* [[Intravenous immunoglobulin]] ([[IVIG]]) | *[[Intravenous immunoglobulin]] ([[IVIG]]) | ||
* [[Immunosupressive drug|Immunosupressants]] ([[Alemtuzumab|Alemtuzemab]] [[Azathioprine]] [[Cyclophosphamide]] [[Cyclosporine|Cyclosporin]] [[Etanercept]] [[Interferon-alpha]]) | *[[Immunosupressive drug|Immunosupressants]] ([[Alemtuzumab|Alemtuzemab]] [[Azathioprine]] [[Cyclophosphamide]] [[Cyclosporine|Cyclosporin]] [[Etanercept]] [[Interferon-alpha]]) | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[Multifocal motor neuropathy|Multifocal Motor Neuropathy]]''' | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[Multifocal motor neuropathy|Multifocal Motor Neuropathy]]''' | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* [[Immune response|Abnormal immune response]] ([[Anti-ganglioside antibodies|Anti ganglioside]] [[Anti-ganglioside antibodies|GM-1]] [[IgM]] [[antibodies]]) | *[[Immune response|Abnormal immune response]] ([[Anti-ganglioside antibodies|Anti ganglioside]] [[Anti-ganglioside antibodies|GM-1]] [[IgM]] [[antibodies]]) | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* Progressive, asymmetric, distal and upper [[Limb (anatomy)|limb]] predominant weakness | * Progressive, asymmetric, distal and upper [[Limb (anatomy)|limb]] predominant weakness | ||
* No significant [[sensory]] abnormalities | * No significant [[sensory]] abnormalities | ||
* [[Areflexia]] | *[[Areflexia]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* Elevated [[CSF]] [[protein]] | * Elevated [[CSF]] [[protein]] | ||
Line 260: | Line 283: | ||
* | * | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* [[Intravenous immunoglobulin|Intravenous immunoglobulins]] | *[[Intravenous immunoglobulin|Intravenous immunoglobulins]] | ||
* [[Cyclophosphamide]] | *[[Cyclophosphamide]] | ||
* [[Rituximab]] | *[[Rituximab]] | ||
|- | |- | ||
| style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|'''Organ System Involvement'''}} | | style="background: #4479BA; width: 200px;" |{{fontcolor|#FFF|'''Organ System Involvement'''}} | ||
| style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|'''Differential Diagnosis'''}} | | style="background: #4479BA; width: 200px;" |{{fontcolor|#FFF|'''Differential Diagnosis'''}} | ||
| style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|'''Causes'''}} | | style="background: #4479BA; width: 200px;" |{{fontcolor|#FFF|'''Causes'''}} | ||
| style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|'''Features'''}} | | style="background: #4479BA; width: 200px;" |{{fontcolor|#FFF|'''Features'''}} | ||
| style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Laboratory Findings}} | | style="background: #4479BA; width: 200px;" |{{fontcolor|#FFF|Laboratory Findings}} | ||
| style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Gold Standard Test}} | | style="background: #4479BA; width: 200px;" |{{fontcolor|#FFF|Gold Standard Test}} | ||
| style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|'''Therapy'''}} | | style="background: #4479BA; width: 200px;" |{{fontcolor|#FFF|'''Therapy'''}} | ||
|- | |- | ||
| rowspan="7" style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''''Organomegaly (Hepatosplenomegaly and Lymphadenopathy)''''' | | rowspan="7" style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''''Organomegaly (Hepatosplenomegaly and Lymphadenopathy)''''' | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[Malaria]]''' | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[Malaria]]''' | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* [[Plasmodium falciparum]] | *[[Plasmodium falciparum]] | ||
* [[Plasmodium ovale|P. ovale]] | *[[Plasmodium ovale|P. ovale]] | ||
* [[P. malariae]] | *[[P. malariae]] | ||
* [[Plasmodium knowlesi|P. knowlesi]] | *[[Plasmodium knowlesi|P. knowlesi]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* Tertian ([[Plasmodium vivax|vivax]], [[Plasmodium ovale|ovale]], [[Plasmodium falciparum|falciparum]]), quartan (malariae), quotidian fever ([[Plasmodium knowlesi|knowlesi]]) | * Tertian ([[Plasmodium vivax|vivax]], [[Plasmodium ovale|ovale]], [[Plasmodium falciparum|falciparum]]), quartan (malariae), quotidian fever ([[Plasmodium knowlesi|knowlesi]]) | ||
* [[Vector]] is female [[Anopheles]] mosquito | *[[Vector]] is female [[Anopheles]] mosquito | ||
* [[Hepatosplenomegaly]] | *[[Hepatosplenomegaly]] | ||
* [[Lymphadenopathy]] | *[[Lymphadenopathy]] | ||
* [[Jaundice]] | *[[Jaundice]] | ||
* [[Icterus (medicine)|Icterus]] | *[[Icterus (medicine)|Icterus]] | ||
* [[Tachycardia]] | *[[Tachycardia]] | ||
* [[Tachypnea]] | *[[Tachypnea]] | ||
* [[Productive cough]] | *[[Productive cough]] | ||
* [[Hematuria]] | *[[Hematuria]] | ||
* [[Altered mental status]] | *[[Altered mental status]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* [[Microcytic anemia]] | *[[Microcytic anemia]] | ||
* [[Malaria differential diagnosis|Thick and thin blood films]] ([[Giemsa stain|Giemsa staining]]) | *[[Malaria differential diagnosis|Thick and thin blood films]] ([[Giemsa stain|Giemsa staining]]) | ||
* Rapid diagnostic test ([[antigen]] detection | * Rapid diagnostic test ([[antigen]] detection | ||
* [[Polymerase chain reaction]] ([[Polymerase chain reaction|PCR]]) | *[[Polymerase chain reaction]] ([[Polymerase chain reaction|PCR]]) | ||
* [[Enzyme linked immunosorbent assay (ELISA)|Enzyme linked immunosorbent assay]] ([[Enzyme linked immunosorbent assay (ELISA)|ELISA]]) | *[[Enzyme linked immunosorbent assay (ELISA)|Enzyme linked immunosorbent assay]] ([[Enzyme linked immunosorbent assay (ELISA)|ELISA]]) | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* [[Malaria differential diagnosis|Thick and thin films]] | *[[Malaria differential diagnosis|Thick and thin films]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* Non-[[Plasmodium falciparum|falciparum]] species: | * Non-[[Plasmodium falciparum|falciparum]] species: | ||
** [[Chloroquine]] (in susceptible) | **[[Chloroquine]] (in susceptible) | ||
** [[Artemisinin]] plus [[Mefloquine|mefloquin]] or [[lumefantrine]] (in [[chloroquine]] resistant) | **[[Artemisinin]] plus [[Mefloquine|mefloquin]] or [[lumefantrine]] (in [[chloroquine]] resistant) | ||
* [[Plasmodium falciparum|Falciparum]] species: | *[[Plasmodium falciparum|Falciparum]] species: | ||
** [[Chloroquine]] (in susceptible) | **[[Chloroquine]] (in susceptible) | ||
** [[Artemether]] plus [[lumefantrine]] (in [[Chloroquine|chloroquin]] resistant) OR | **[[Artemether]] plus [[lumefantrine]] (in [[Chloroquine|chloroquin]] resistant) OR | ||
** [[Artesunate]] plus [[Mefloquine|mefloquin]] OR | **[[Artesunate]] plus [[Mefloquine|mefloquin]] OR | ||
** [[Artesunate]] plus [[Sulfadoxine|sulfadoxine-pyrimethamine]] | **[[Artesunate]] plus [[Sulfadoxine|sulfadoxine-pyrimethamine]] | ||
** [[Atovaquone-Proguanil|Atovaquone plus proguanil]] | **[[Atovaquone-Proguanil|Atovaquone plus proguanil]] | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[Kala-azar]]''' | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[Kala-azar]]''' | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* [[Leishmaniasis|Leshmania donovani]] | *[[Leishmaniasis|Leshmania donovani]] | ||
* L. infantum | * L. infantum | ||
* L. chagasi | * L. chagasi | ||
Line 319: | Line 342: | ||
* | * | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* [[Fever]] | *[[Fever]] | ||
* Vector is [[sandfly]] | * Vector is [[sandfly]] | ||
* [[Hepatosplenomegaly]] | *[[Hepatosplenomegaly]] | ||
* [[Lymphadenopathy]] | *[[Lymphadenopathy]] | ||
* [[Hyperpigmentation]] | *[[Hyperpigmentation]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* [[Anemia]] | *[[Anemia]] | ||
* [[Direct agglutination test]] (DAT) | *[[Direct agglutination test]] (DAT) | ||
* rk39 dipstick | * rk39 dipstick | ||
* [[Enzyme linked immunosorbent assay (ELISA)|ELISA]] | *[[Enzyme linked immunosorbent assay (ELISA)|ELISA]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* [[Splenic]] aspiration | *[[Splenic]] aspiration | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* [[Liposomal amphotericin B]] | *[[Liposomal amphotericin B]] | ||
* [[Sodium stibogluconate]] | *[[Sodium stibogluconate]] | ||
* [[Pentamidine]] | *[[Pentamidine]] | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[Hepatitis|Infective Hepatitis]]''' | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[Hepatitis|Infective Hepatitis]]''' | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* [[Hepatitis A virus|Hepatitis A virus (HAV)]] | *[[Hepatitis A virus|Hepatitis A virus (HAV)]] | ||
* [[HBV]] | *[[HBV]] | ||
* [[Hepatitis C|HCV]] | *[[Hepatitis C|HCV]] | ||
* [[Hepatitis D|HDV]] (co-infection with [[HBV]]) | *[[Hepatitis D|HDV]] (co-infection with [[HBV]]) | ||
* [[Hepatitis E|HEV]] | *[[Hepatitis E|HEV]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* [[Fever]] | *[[Fever]] | ||
* Transmitted via [[fecal-oral route]] ([[Hepatitis A|HAV]], [[Hepatitis B virus|HBV]], [[HDV]], [[HEV]]), infected sera ([[HCV]]), [[sexual contact]] with infected individuals | * Transmitted via [[fecal-oral route]] ([[Hepatitis A|HAV]], [[Hepatitis B virus|HBV]], [[HDV]], [[HEV]]), infected sera ([[HCV]]), [[sexual contact]] with infected individuals | ||
* [[Hepatosplenomegaly]] (may become shrunken in cases of [[cirrhosis]] due to chronic infection) | *[[Hepatosplenomegaly]] (may become shrunken in cases of [[cirrhosis]] due to chronic infection) | ||
* [[Lymphadenopathy]] | *[[Lymphadenopathy]] | ||
* [[Jaundice]] | *[[Jaundice]] | ||
* [[Palmar erythema]] | *[[Palmar erythema]] | ||
* [[Spider angiomata]] | *[[Spider angiomata]] | ||
* [[Gynecomastia]] | *[[Gynecomastia]] | ||
* [[Arthritis-dermatitis syndrome]] | *[[Arthritis-dermatitis syndrome]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* [[Antigen]] and [[antibody]] detection | *[[Antigen]] and [[antibody]] detection | ||
* Total and direct [[bilirubin]] (increased) | * Total and direct [[bilirubin]] (increased) | ||
* Severe disease is often associated with persistent [[bilirubin]] levels >340 mmol/L | * Severe disease is often associated with persistent [[bilirubin]] levels >340 mmol/L | ||
* [[ALT]] and [[AST]] (increased) | *[[ALT]] and [[AST]] (increased) | ||
* [[Alkaline phosphatase]] (normal or mildly elevated) | *[[Alkaline phosphatase]] (normal or mildly elevated) | ||
* [[Prothrombin time]] (prolonged from synthetic defect, caused by hepatocellular [[necrosis]]) | *[[Prothrombin time]] (prolonged from synthetic defect, caused by hepatocellular [[necrosis]]) | ||
* [[Total protein]] (decreased) | *[[Total protein]] (decreased) | ||
* [[Globulin]] (mildly elevated) | *[[Globulin]] (mildly elevated) | ||
* Initial [[lymphopenia]] and [[neutropenia]], followed by relative [[lymphocytosis]] | * Initial [[lymphopenia]] and [[neutropenia]], followed by relative [[lymphocytosis]] | ||
* [[Anemia|Low hemoglobin]] | *[[Anemia|Low hemoglobin]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* [[Antigen]] and [[antibody]] detection | *[[Antigen]] and [[antibody]] detection | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* [[Interferon]] ([[IFN]]) | *[[Interferon]] ([[IFN]]) | ||
* [[Antivirals|Nucleoside analogs]] | *[[Antivirals|Nucleoside analogs]] | ||
* [[Antivirals|Nucleotide analogs]] | *[[Antivirals|Nucleotide analogs]] | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[Chronic myelogenous leukemia|Chronic Myelogenous Leukemia]] (CML)''' | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[Chronic myelogenous leukemia|Chronic Myelogenous Leukemia]] (CML)''' | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* [[Philadelphia chromosome|BCR/ABL gene]] fusion product due to [[Chromosomal translocation|translocation]] [[mutation]] [[Philadelphia chromosome|t(9;22)]](q34;q11) | *[[Philadelphia chromosome|BCR/ABL gene]] fusion product due to [[Chromosomal translocation|translocation]] [[mutation]] [[Philadelphia chromosome|t(9;22)]](q34;q11) | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* [[Fever]] | *[[Fever]] | ||
* [[Weight loss]] | *[[Weight loss]] | ||
* [[Hepatosplenomegaly]] | *[[Hepatosplenomegaly]] | ||
* [[Lymphadenopathy]] | *[[Lymphadenopathy]] | ||
* [[Bruises]] | *[[Bruises]] | ||
* [[Petechiae]] | *[[Petechiae]] | ||
* [[Ulcers]] | *[[Ulcers]] | ||
* [[Vesicles]] | *[[Vesicles]] | ||
* [[Malaise]] | *[[Malaise]] | ||
* [[Early satiety]] | *[[Early satiety]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* [[Anemia]] | *[[Anemia]] | ||
* [[Leukocytosis]] (median of 100,000/µL) with a [[left shift]] | *[[Leukocytosis]] (median of 100,000/µL) with a [[left shift]] | ||
* [[Thrombocytosis]] | *[[Thrombocytosis]] | ||
* [[Blast|Blasts]] usually <2% | *[[Blast|Blasts]] usually <2% | ||
* Absolute [[basophilia]] | * Absolute [[basophilia]] | ||
* Absolute [[eosinophilia]] | * Absolute [[eosinophilia]] | ||
* [[Monocytosis]] | *[[Monocytosis]] | ||
* [[Thrombocytosis]] | *[[Thrombocytosis]] | ||
* [[Thrombocytopenia]] suggests an alternative diagnosis or the presence of advanced stage | *[[Thrombocytopenia]] suggests an alternative diagnosis or the presence of advanced stage | ||
* Elevated [[uric acid]] | * Elevated [[uric acid]] | ||
* Elevated [[histamine]] levels | * Elevated [[histamine]] levels | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* [[Fluorescence in situ hybridization|Fluoroscent insitu hybridization (FISH)]] | *[[Fluorescence in situ hybridization|Fluoroscent insitu hybridization (FISH)]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* [[Imatinib]] | *[[Imatinib]] | ||
* [[Dasatinib]] | *[[Dasatinib]] | ||
* [[Nilotinib]] | *[[Nilotinib]] | ||
* [[Bosutinib]] | *[[Bosutinib]] | ||
* [[Ponatinib]] | *[[Ponatinib]] | ||
* [[Cytarabine]] | *[[Cytarabine]] | ||
* [[Cytarabine|HDAC]] (high-dose [[cytarabine]]) | *[[Cytarabine|HDAC]] (high-dose [[cytarabine]]) | ||
* [[Hydroxyurea]] | *[[Hydroxyurea]] | ||
* [[Busulfan]] | *[[Busulfan]] | ||
* [[Busulfex]] | *[[Busulfex]] | ||
* [[Stem cell transplantation]] | *[[Stem cell transplantation]] | ||
|- | |- | ||
Line 421: | Line 444: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* Various causes based on type: | * Various causes based on type: | ||
** [[Hodgkin's lymphoma|Hodgkin's]] | **[[Hodgkin's lymphoma|Hodgkin's]] | ||
** [[Non-Hodgkin lymphoma|Non-Hodgkin's]] | **[[Non-Hodgkin lymphoma|Non-Hodgkin's]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* [[Fever]] | *[[Fever]] | ||
* [[Weight loss]] | *[[Weight loss]] | ||
* [[Lymphadenopathy]] | *[[Lymphadenopathy]] | ||
* [[Hepatosplenomegaly]] | *[[Hepatosplenomegaly]] | ||
* [[Night sweats]], constant [[fatigue]] | *[[Night sweats]], constant [[fatigue]] | ||
* Purplish scaly rash in cases of [[cutaneous lymphoma]] | * Purplish scaly rash in cases of [[cutaneous lymphoma]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* [[Erythrocyte sedimentation rate|Elevated ESR]] | *[[Erythrocyte sedimentation rate|Elevated ESR]] | ||
* [[C-reactive protein|Increased CRP]] | *[[C-reactive protein|Increased CRP]] | ||
* [[Lactate dehydrogenase|Increased LDH]] | *[[Lactate dehydrogenase|Increased LDH]] | ||
* [[Anemia of chronic disease]] | *[[Anemia of chronic disease]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* [[Lymph node biopsy]] | *[[Lymph node biopsy]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
Line 444: | Line 467: | ||
* Aggregation and deposition of [[immunoglobulin light chains]] that are usually produced by [[plasma cell]] clones | * Aggregation and deposition of [[immunoglobulin light chains]] that are usually produced by [[plasma cell]] clones | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* [[Nephrotic syndrome]] ([[peripheral edema]]) | *[[Nephrotic syndrome]] ([[peripheral edema]]) | ||
* [[Restrictive cardiomyopathy]] ([[fatigue]], [[dyspnea]], [[syncope]]) | *[[Restrictive cardiomyopathy]] ([[fatigue]], [[dyspnea]], [[syncope]]) | ||
* [[Peripheral neuropathy]] ([[numbness]], [[tingling]]) | *[[Peripheral neuropathy]] ([[numbness]], [[tingling]]) | ||
* [[Hepatomegaly]] with elevated [[liver enzymes]] | *[[Hepatomegaly]] with elevated [[liver enzymes]] | ||
* [[Macroglossia]] | *[[Macroglossia]] | ||
* [[Purpura]] | *[[Purpura]] | ||
* [[Bleeding diathesis]] | *[[Bleeding diathesis]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* Typical green birefringence under polarized light after Congo red staining (appears in red under normal light) | * Typical green birefringence under polarized light after Congo red staining (appears in red under normal light) | ||
Line 457: | Line 480: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* Melphalan-prednisone/dexamethasone | * Melphalan-prednisone/dexamethasone | ||
* Dexamethasone plus Cyclophosphamide-thalidomide | * Dexamethasone plus Cyclophosphamide-thalidomide | ||
* Stem cell transplantation | * Stem cell transplantation | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[Gaucher's disease|Gaucher's Disease]]''' | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[Gaucher's disease|Gaucher's Disease]]''' | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* [[GBA (gene)|GBA gene]] [[mutation]] | *[[GBA (gene)|GBA gene]] [[mutation]] | ||
* Aberrant metabolism of [[glucocerebroside]] ([[lipid]]) | * Aberrant metabolism of [[glucocerebroside]] ([[lipid]]) | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* [[Hydrops fetalis]] | *[[Hydrops fetalis]] | ||
* Dry, scaly skin ([[ichthyosis]]) or other [[skin]] abnormalities | * Dry, scaly skin ([[ichthyosis]]) or other [[skin]] abnormalities | ||
* [[Hepatosplenomegaly]] | *[[Hepatosplenomegaly]] | ||
* Distinctive facial features | * Distinctive facial features | ||
* [[Neurological disorder|Neurological problems]] | *[[Neurological disorder|Neurological problems]] | ||
* [[Gall stones]] | *[[Gall stones]] | ||
* [[Growth retardation]] | *[[Growth retardation]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* [[Hypocholesterolemia]] | *[[Hypocholesterolemia]] | ||
* [[Splenic]] nodules | *[[Splenic]] nodules | ||
* [[Cytopenias]] (especially [[thrombocytopenia]]) | *[[Cytopenias]] (especially [[thrombocytopenia]]) | ||
* Increased [[ferritin]] levels | * Increased [[ferritin]] levels | ||
* Increased tartarate resistant acid phosphatase (TRAP) levels | * Increased tartarate resistant acid phosphatase (TRAP) levels | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* Enzyme assay for [[glucocerebrosidase]] | * Enzyme assay for [[glucocerebrosidase]] | ||
* [[DNA|DNA analysis]] for [[GBA (gene)|GBA mutation]] | *[[DNA|DNA analysis]] for [[GBA (gene)|GBA mutation]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* [[Enzyme replacement therapy|Enzyme replacement]] | *[[Enzyme replacement therapy|Enzyme replacement]] | ||
* [[Splenectomy]] | *[[Splenectomy]] | ||
* [[Blood transfusion]] | *[[Blood transfusion]] | ||
|- | |- | ||
| style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF| |'''Organ System Involvement'''}} | | style="background: #4479BA; width: 200px;" |{{fontcolor|#FFF| |'''Organ System Involvement'''}} | ||
| style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|'''Differential Diagnosis'''}} | | style="background: #4479BA; width: 200px;" |{{fontcolor|#FFF|'''Differential Diagnosis'''}} | ||
| style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|'''Causes'''}} | | style="background: #4479BA; width: 200px;" |{{fontcolor|#FFF|'''Causes'''}} | ||
| style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|'''Features'''}} | | style="background: #4479BA; width: 200px;" |{{fontcolor|#FFF|'''Features'''}} | ||
| style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Laboratory Findings}} | | style="background: #4479BA; width: 200px;" |{{fontcolor|#FFF|Laboratory Findings}} | ||
| style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Gold Standard Test}} | | style="background: #4479BA; width: 200px;" |{{fontcolor|#FFF|Gold Standard Test}} | ||
| style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|'''Therapy'''}} | | style="background: #4479BA; width: 200px;" |{{fontcolor|#FFF|'''Therapy'''}} | ||
|- | |- | ||
| rowspan="7" style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''''Cardiac Failure''''' | | rowspan="7" style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''''Cardiac Failure''''' | ||
Line 543: | Line 566: | ||
* | * | ||
|- | |- | ||
| style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|'''Organ System Involvement'''}} | | style="background: #4479BA; width: 200px;" |{{fontcolor|#FFF|'''Organ System Involvement'''}} | ||
| style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|'''Differential Diagnosis'''}} | | style="background: #4479BA; width: 200px;" |{{fontcolor|#FFF|'''Differential Diagnosis'''}} | ||
| style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|'''Causes'''}} | | style="background: #4479BA; width: 200px;" |{{fontcolor|#FFF|'''Causes'''}} | ||
| style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|'''Features'''}} | | style="background: #4479BA; width: 200px;" |{{fontcolor|#FFF|'''Features'''}} | ||
| style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Laboratory Findings}} | | style="background: #4479BA; width: 200px;" |{{fontcolor|#FFF|Laboratory Findings}} | ||
| style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Gold Standard Test}} | | style="background: #4479BA; width: 200px;" |{{fontcolor|#FFF|Gold Standard Test}} | ||
| style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|'''Therapy'''}} | | style="background: #4479BA; width: 200px;" |{{fontcolor|#FFF|'''Therapy'''}} | ||
|- | |- | ||
| rowspan="4" style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''''Plasma Cell Dyscrasias''''' | | rowspan="4" style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''''Plasma Cell Dyscrasias''''' | ||
Line 563: | Line 586: | ||
*[[Anemia]] | *[[Anemia]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* [[Anemia]] | *[[Anemia]] | ||
* [[Thrombocytopenia]] | *[[Thrombocytopenia]] | ||
* [[Leukopenia]] | *[[Leukopenia]] | ||
* Decreased albumin (reversed albumin:globulin ratio) | * Decreased albumin (reversed albumin:globulin ratio) | ||
* Increased serum creatinine, urea | * Increased serum creatinine, urea | ||
Line 574: | Line 597: | ||
* Bence-Jones proteins in urine | * Bence-Jones proteins in urine | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* Clonal plasma cells on bone marrow exam greater than equal to 10% | * Clonal plasma cells on bone marrow exam greater than equal to 10% | ||
AND | AND | ||
* Any one of the following: | * Any one of the following: | ||
** Evidence of end-organ damage | ** Evidence of end-organ damage | ||
Line 594: | Line 619: | ||
*Clonal [[plasma cell]] proliferation | *Clonal [[plasma cell]] proliferation | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* [[Asymptomatic]] | *[[Asymptomatic]] | ||
* | * | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* [[Serum]] [[M protein]] of <3 g/L | *[[Serum]] [[M protein]] of <3 g/L | ||
* Fewer than 10% [[plasma cells]] in the [[bone marrow]] | * Fewer than 10% [[plasma cells]] in the [[bone marrow]] | ||
* No evidence of [[bone]] or [[Organ (anatomy)|organ]] damage | * No evidence of [[bone]] or [[Organ (anatomy)|organ]] damage | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* Serum M protein (IgG or IgA) <3g/dl | * Serum M protein (IgG or IgA) <3g/dl | ||
AND | AND | ||
* Clonal bone marrow plasma cells < 10% | * Clonal bone marrow plasma cells < 10% | ||
AND | AND | ||
* No end-organ damage | * No end-organ damage | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
Line 616: | Line 645: | ||
*Clonal [[plasma cell]] proliferation | *Clonal [[plasma cell]] proliferation | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* [[Asymptomatic]] | *[[Asymptomatic]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* [[Serum]] [[M protein]] of greater than equal to 3 g/L | *[[Serum]] [[M protein]] of greater than equal to 3 g/L | ||
* Greater than 10% [[plasma cells]] in the [[bone marrow]] | * Greater than 10% [[plasma cells]] in the [[bone marrow]] | ||
* No evidence of [[bone]] or [[Organ (anatomy)|organ]] damage | * No evidence of [[bone]] or [[Organ (anatomy)|organ]] damage | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* Serum M protein (IgG or IgA greater than equal to 3 g/dl | * Serum M protein (IgG or IgA greater than equal to 3 g/dl | ||
OR | OR | ||
* Urinary M protein greater than equal to 500 mg/24 h | * Urinary M protein greater than equal to 500 mg/24 h | ||
AND/OR | AND/OR | ||
* Clonal bone marrow plasma cells 10-60% | * Clonal bone marrow plasma cells 10-60% | ||
AND | AND | ||
* No end-organ damage | * No end-organ damage | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | |
Revision as of 15:16, 30 October 2019
Primary amyloidosis Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Primary amyloidosis differential diagnosis On the Web |
American Roentgen Ray Society Images of Primary amyloidosis differential diagnosis |
Risk calculators and risk factors for Primary amyloidosis differential diagnosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Overview
- Differentiating Primary amyloidosis from Other Diseases
Organ System Involvement | Differential Diagnosis | Causes | Clinical Features | Laboratory Findings | Gold Standard Test | Therapy |
---|---|---|---|---|---|---|
Nephrotic Syndrome and Real Failure | Primary (AL) Amyloidosis |
|
|
|
|
|
Diabetic Nephropathy |
|
|
|
|
||
Minimal Change Disease |
|
|||||
Focal Segmental Glomerulosclerosis | ||||||
Fabry's Disease | ||||||
Light Chain Deposition Disease | ||||||
Membranous Glomerulonephritis | ||||||
Fibrillary-Immunotactoid Glomerulopathy | ||||||
Organ System Involvement | Differential Diagnosis | Causes | Clinical Features | Laboratory Findings | Gold Standard Test | Therapy |
Polyneuropathy | POEMS syndrome (Demyelinating) |
|
|
|||
Metabolic Syndrome (Axonal pathology) |
|
|
|
|||
Vitamin Deficiencies (Axonal Pathology) |
|
|
|
| ||
Guillain-Barre Syndrome (Demyelinating) |
|
|
|
|||
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (Mixed axonal and demyelinatiing) |
|
|
|
|
||
Multifocal Motor Neuropathy |
|
|||||
Organ System Involvement | Differential Diagnosis | Causes | Features | Laboratory Findings | Gold Standard Test | Therapy |
Organomegaly (Hepatosplenomegaly and Lymphadenopathy) | Malaria |
|
|
| ||
Kala-azar |
|
|
|
|||
Infective Hepatitis |
|
|
||||
Chronic Myelogenous Leukemia (CML) |
|
|
||||
Lymphoma |
|
|
||||
Primary (AL) Amyloidosis |
|
|
|
| ||
Gaucher's Disease |
|
|
|
|
||
Organ System Involvement | Differential Diagnosis | Causes | Features | Laboratory Findings | Gold Standard Test | Therapy |
Cardiac Failure |
|
|
|
| ||
|
| |||||
|
|
| ||||
| ||||||
| ||||||
|
|
| ||||
| ||||||
Organ System Involvement | Differential Diagnosis | Causes | Features | Laboratory Findings | Gold Standard Test | Therapy |
Plasma Cell Dyscrasias | Multiple myeloma |
|
|
|
AND
|
|
Monoclonal gammopathy of undetermined significance (MGUS) |
|
|
AND
AND
|
| ||
Asymptomatic Plasma Cell Myeloma |
|
|
OR
AND/OR
AND
|
| ||
Plasmacytoma |
|
|
|
|
| |
Skin Changes | Scurvy |
|
|